CRISPR Therapeutics (NASDAQ: CRSP) is a company that can potentially help revolutionize healthcare. Its gene-editing therapies can be game changers for patients living with illnesses and conditions ...
CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory. The company ...
CRISPR Therapeutics AG (NASDAQ:CRSP) also received a rating update from JPMorgan on February 16. The firm cut the price ...
Casgevy is starting to build some serious sales momentum. CRISPR Therapeutics also has a deep pipeline and healthy funding. The stock requires patience, but there is a visible path to a bright future.
Gene therapy and gene editing are marvels of modern biotechnology, providing revolutionary techniques for fixing genetic abnormalities. Gene therapy introduces functional genetic material to ...
CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. First, let's talk a bit about ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results